TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7996800
Drug: Active kallikrein
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active kallikrein excretion
Study: 27237769
Drug: IM IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM IFN beta‐1a 30 mcg once weekly (full-dose group)
Study: 27237769
Drug: IM IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM IFN beta‐1a 15 mcg once weekly for 2 weeks then 30 mcg once weekly (titration group)
Study: 24508036
Drug: 100μg gE/AS01B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100μg gE/AS01B (one dose)
Study: 24508036
Drug: 25μg gE/AS01B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25μg gE/AS01B (two doses, two months apart)
Study: 24508036
Drug: 50μg gE/AS01B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50μg gE/AS01B (two doses, two months apart)
Study: 24508036
Drug: 100μg gE/AS01B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100μg gE/AS01B (two doses, two months apart)
Study: 24508036
Drug: 100μg gE/saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100μg gE/saline (two doses, two months apart)
Study: 22730850
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein milk supplement
Study: 22730850
Drug: Higher carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher carbohydrate supplement
Study: 20414783
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A 2% drops
Study: 18498912
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of aceclofenac 100 mg
Study: 18498912
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of aceclofenac 100 mg
Study: 15342210
Drug: Enoxaparin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1.5 mg/kg subcutaneous (s.c.) once daily
Study: 15342210
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) intravenous (i.v.) adjusted to aPTT 1.5‐2.5 times control
Study: 11249891
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 16 mg, uptitrated to 32 mg after 4 weeks
Study: 11249891
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg, uptitrated to 10 mg after 4 weeks
Study: 8049846
Drug: Amiloride (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (0.3 mg/m2 body surface area)
Study: 3352886
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (steroids preoperatively and for 4 days postoperatively)
Study: 3352886
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (steroids pre- and postoperatively for 1 day)
Study: 3352886
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (no steroids)
Study: 28068207
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution activated by diode laser
Study: 28068207
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution with methylene blue dye activated by diode laser
Study: 28068207
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (positive control)
Study: 25724847
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (3 mg, six 2-monthly oral doses over 1 year)
Study: 20609398
Drug: DTaP(5)‐IPV/Hib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP(5)‐IPV/Hib administered concurrently with PCV7
Study: 20609398
Drug: DTaP(5)‐IPV/Hib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP(5)‐IPV/Hib administered at separate visits (staggered group)
Study: 16984993
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone therapy (Intrinsa)
Study: 16984993
Drug: Oral methyltestosterone
Normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methyltestosterone
Study: 10671676
Drug: CAV/PE‐W (dose‐intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV/PE‐W (dose‐intensive weekly alternating chemotherapy)
Study: 10671676
Drug: CAV/PE (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV/PE (standard alternating chemotherapy)
Study: 8148854
Drug: Flurbiprofen 200
Normalized name: flurbiprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 200 mg sustained-release
Study: 8148854
Drug: Ketoprofen 200
Normalized name: ketoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 200 mg sustained-release
Study: 3484547
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug change (control)
Study: 3484547
Drug: Addition or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition or deletion of a single drug other than barbiturate
Study: 22689417
Drug: Ranolazine (750/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (750/1000 mg bid)
Study: 20938175
Drug: Antofloxacin hydrochloride
Normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antofloxacin hydrochloride (400 mg loading dose on day 1, followed by 200 mg daily)
Study: 20938175
Drug: Levofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (200 mg orally twice daily for 7-14 days)
Study: 18549888
Drug: VBLOC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBLOC therapy (intra-abdominal vagal blocking)
Study: 18549888
Drug: VBLOC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBLOC therapy
Study: 9076203
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg tablet)
Study: 22639944
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (eight weeks of weekly teacher-led yoga class and home-based daily yoga practice delivered by DVD)
Study: 17295995
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with incentives I
Study: 17295995
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with incentives II
Study: 9349928
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg per day)
Study: 2879344
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HO) with diazepam (5 mg) in group I
Study: 29349539
Drug: Experimental bundle
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental bundle with intraperitoneal lavage with antibiotic solution, fascial closure with Triclosan-coated sutures, and Mupirocin ointment application on skin staples
Study: 25281223
Drug: MDMA (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (0.5 or 1.0 mg/kg)
Study: 17959585
Drug: i.v. acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. acetaminophen
Study: 11094668
Drug: Midazolam 3
Normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3 mg administered at 1 minute prior to propofol
Study: 11094668
Drug: Midazolam 3
Normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3 mg administered at 2 minutes prior to propofol
Study: 11094668
Drug: Midazolam 3
Normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3 mg administered at 4 minutes prior to propofol
Study: 11094668
Drug: Midazolam 3
Normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3 mg administered at 6 minutes prior to propofol
Study: 11094668
Drug: Midazolam 3
Normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3 mg administered at 10 minutes prior to propofol
Study: 31865288
Drug: Chakrayoga Meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chakrayoga Meditation Program (twice a week for 2 hours during 6 weeks, consisting of 1 hour of Chakrayoga and 1 hour of meditation)
Study: 29079365
Drug: Continuous-flow cryocompression
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-flow cryocompression therapy (CFCT)
Study: 25875777
Drug: Deferoxamine mesylate
Normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine mesylate (62 mg/kg/day, maximum dose not to exceed 6000 mg/day)
Study: 25087476
Drug: Low-dose DENVax
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DENVax vaccine
Study: 25087476
Drug: High-dose DENVax
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DENVax vaccine
Study: 25087476
Drug: Placebo (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo (low-dose)
Study: 25087476
Drug: Placebo (high-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (high-dose)
Study: 18633464
Drug: Frequent Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent Therapy (FT)
Study: 18633464
Drug: Minimal Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Therapy (MT)
Study: 12135015
Drug: L‐NMMA (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (12 mg/kg within 5 min, followed by a maintenance infusion of 6.7 mg/kg/h i.v.)
Study: 8523851
Drug: Drug-resistant pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-resistant pulmonary tuberculosis patients continuing chemotherapy
Study: 8523851
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with drug-resistant tuberculosis
Study: 8523851
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with drug-resistant pulmonary tuberculosis
Study: 6779371
Drug: Metronidazole (600‐1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (600‐1200 mg daily)
Study: 6779371
Drug: Phenoxymethyl penicillin
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethyl penicillin (1.6 g daily)
Study: 30378087
Drug: Glycopyrronium tosylate
Normalized name: glycopyrronium tosylate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium tosylate (GT) 3.75% applied once daily for 4 weeks
Study: 25881461
Drug: Xingnaojing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing Injection (20 mL per day for 14 days), followed by Chinese medical granules for 21 days, and Naoxueshu Oral Liquid (10 mL, 3 times per day till 3 months)
Study: 25881461
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment of Western internal medicine
Study: 19729890
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus oral cholecalciferol (150,000 IU once a month for the first 2 months, followed by 90,000 IU once a month for the last 4 months)
Study: 19729890
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus monthly placebo
Study: 11718495
Drug: Cycloserine 500
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloserine 500 mg after a 12-hour fast (reference)
Study: 11718495
Drug: Cycloserine 500
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloserine 500 mg with a high-fat meal
Study: 11718495
Drug: Cycloserine 500
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloserine 500 mg with orange juice
Study: 11718495
Drug: Cycloserine 500
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloserine 500 mg with antacids
Study: 8239101
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg/10 mL) administered at 10 mL/min for ten minutes, with up to 3 mg of open-label flumazenil if no response.
Study: 8239101
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL/min) administered for ten minutes.
Study: 23661528
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement containing forskolin, rutin, and vitamins B1 and B2 for 30 days
Study: 18579283
Drug: Conventional conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional conservative preparation (G1)
Study: 18579283
Drug: Modified preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified preparation with cavosurface bevel (G2)
Study: 16636486
Drug: Tirofiban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (10 mg/kg bolus followed by infusion of 0.15 mg . kg(‐1) . min (‐1) until total dose reached 12.5 mg)
Study: 12006956
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (1.5 mmol/kg per day)
Study: 7473451
Drug: 0.6 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/d of conjugated equine estrogen (CEE) cyclically (n = 15)
Study: 7473451
Drug: 50 micrograms/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/d of transdermal estradiol (E2) cyclically (n = 17)
Study: 7473451
Drug: 0.6 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/d of CEE continuously (n = 17)
Study: 7473451
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of CEE and 2.5 mg/d of MPA continuously (n = 19)
Study: 7473451
Drug: Treatment-free control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-free control group (n = 22)
Study: 6315329
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g daily for two weeks)
Study: 6315329
Drug: Nifedipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (4 X 10 mg daily for four weeks)
Study: 6315329
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg daily for two weeks)
Study: 6315329
Drug: Nifedipine alone
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine alone (4 X 10 mg daily)
Study: 31626571
Drug: Stage-adapted first-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stage-adapted first-line treatment (radiotherapy alone, chemotherapy alone, or combined-modality approaches)
Study: 30275228
Drug: Intraperitoneal paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal paclitaxel followed by paclitaxel, cisplatin, and S‐1 (PCS) chemotherapy
Study: 25549086
Drug: Artemisinin-naphthoquine (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-naphthoquine (three daily doses)
Study: 25549086
Drug: Artemether-lumefantrine (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (six doses over 3 days)
Study: 22332205
Drug: High ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ω‐3 intake (≥0.20 g/d)
Study: 22332205
Drug: Low ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low ω‐3 intake (<0.20 g/d)
Study: 19996989
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (Sex Hormones and Physical Exercise study)
Study: 15972582
Drug: Once-monthly oral
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-monthly oral ibandronate 150 mg
Study: 15972582
Drug: Once-monthly oral
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-monthly oral ibandronate 100 mg
Study: 10720074
Drug: Low-insulin-hypoglycemic condition
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-insulin-hypoglycemic condition (insulin infusion at 1.5 mU/min x kg)
Study: 10720074
Drug: High-insulin-hypoglycemic condition
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-insulin-hypoglycemic condition (insulin infusion at 15.0 mU/min x kg)
Study: 10720074
Drug: Low-insulin-euglycemic condition
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-insulin-euglycemic condition (insulin infusion at 1.5 mU/min x kg)
Study: 10720074
Drug: High-insulin-euglycemic condition
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-insulin-euglycemic condition (insulin infusion at 15.0 mU/min x kg)
Study: 1611649
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg QD
Study: 1611649
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg QD
Study: 1611649
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg QD
Study: 6140343
Drug: Oestradiol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol and testosterone implants
Study: 30561059
Drug: Telmisartan 2
Normalized name: telmisartan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 2 mg/kg q24 PO
Study: 18191732
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (200 mg weekly until ferritin >500 ng/ml, 200 mg monthly thereafter)
Study: 16393724
Drug: Nebulized beta2-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized beta2-agonist
Study: 9869598
Drug: Infliximab (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5-20 mg/kg)
Study: 8703705
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium loading test
Study: 26856618
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone (20mg daily)
Study: 20298820
Drug: Partial body
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial body weight-supported treadmill training (PBWSTT) for 9 weeks, twice weekly.
Study: 20298820
Drug: Overground walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overground walking practice for 9 weeks, twice weekly.
Study: 17381930
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of price discounts and nutrition education
Study: 11731813
Drug: 17D yellow
Normalized name: yellow fever virus strain 17D-204 live antigen Injection [Stamaril]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17D yellow fever vaccine administered at 6 months
Study: 11731813
Drug: 17D yellow
Normalized name: yellow fever virus strain 17D-204 live antigen Injection [Stamaril]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17D yellow fever vaccine administered at 9 months
Study: 28185672
Drug: Cariprazine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine (mean daily dose 4.2 mg)
Study: 28185672
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean daily dose 3.8 mg)
Study: 17928726
Drug: IgY‐GP gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgY‐GP gel subgingivally applied with subgingival scaling and root planing
Study: 17928726
Drug: IgY‐GP gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgY‐GP gel
Study: 15764039
Drug: UVA/UVB +
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA/UVB + topical corticosteroids (Group II)
Study: 7805972
Drug: Ritodrine tablets
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine tablets
Study: 7805972
Drug: Sustained-release capsules
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release capsules
Study: 25380107
Drug: 3% or
Normalized name: Esopho-Cat, 3% oral cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% or 23.4% hypertonic saline (HTS) as bolus therapy
Study: 21618480
Drug: Avotermin 500
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avotermin 500 ng per 100 µl per linear cm of wound margin, administered by intradermal injection to the groin and distal wound margins of one leg.
Study: 21618480
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered to the other leg.
Study: 15865549
Drug: Piperacillin/tazobactam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (4 g/0.5 g q8h)
Study: 15865549
Drug: Ampicillin/sulbactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (2 g/1 g q6h)
Study: 11206417
Drug: Insulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1 mU/kg/min)